Trials / Completed
CompletedNCT05822180
Evaluation of the Efficacy and Safety of Nano-S1
Evaluation of the Efficacy and Safety of Nano-S1 in Adult Patients Infected With SARS-Cov-2: "COVID Nano-S1
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- General Administration of Military Health, Tunisia · Network
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to assess the efficacy of the efficacy and safety of investigational drug (NanoS) in patients with mild to moderate COVID-19 at high risk for progression to severe COVID-19, including death.
Detailed description
We conducted a prospective randomized double-blind clinical trial over five months to determine the efficacy of NanoS compared to placebo. The effectiveness of treatment was measured by the significant decline in the number of cases of covid-19 infection and/or a decrease in the viral load determined by SARS-CoV-2 cycle threshold (Ct) value using RT-PCRs test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NANOS1 , argent colloïdal , | orally, during 5 day |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2022-01-01
- Completion
- 2022-02-20
- First posted
- 2023-04-20
- Last updated
- 2023-04-20
Locations
1 site across 1 country: Tunisia
Source: ClinicalTrials.gov record NCT05822180. Inclusion in this directory is not an endorsement.